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The European Network for Cancer Research in Children and Adolescents (ENCCA) pro-
vides an interaction platform for stakeholders in research and care of children with cancer.
Among ENCCA objectives is the establishment of biology-based prioritization mechanisms
for the selection of innovative targets, drugs, and prognostic markers for validation in clin-
ical trials. Speciﬁcally for sarcomas, there is a burning need for novel treatment options,
since current chemotherapeutic treatment protocols have met their limits. This is most
obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below
20%. Despite signiﬁcant progress in our understanding of ES biology, clinical translation
of promising laboratory results has not yet taken place due to fragmentation of research
and lack of an institutionalized discussion forum. To ﬁll this gap, ENCCA assembled 30
European expert scientists and ﬁve North American opinion leaders in December 2011
to exchange thoughts and discuss the state of the art in ES research and latest results
from the bench, and to propose biological studies and novel promising therapeutics for the
upcoming European EWING2008 and EWING2012 clinical trials.
Keywords: Ewing sarcoma, animal models, sarcomagenesis, genomics, epigenetics, biomarkers, drug screen,
prognosis
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THE EUROPEAN NETWORK FOR CANCER RESEARCH IN
CHILDREN AND ADOLESCENTS
Biomedical laboratory research into the origins and speciﬁcs of
cancer has led to an almost logarithmic increment of biolog-
ical knowledge over the last decade, clinical translation of this
knowledge, however, is lagging far behind. Owing to multimodal
treatment concepts in (international) multicenter trials, the prog-
nosis has markedly improved in pediatric cancers within the past
decades.Yet for more than 20 years now a plateau has been reached
with regard to standard chemotherapeutic regimens. Although the
clinical trials have clearly been of enormous beneﬁt to patients, the
rigid structure, and long duration of the trials restrict options for
the clinical development of new therapeutics and the prospec-
tive testing of novel prognostic markers. One of the aims of the
European Network for Cancer Research in Children and Adoles-
cents (ENCCA), supported by the Framework Program 7 of the
European Commission, is therefore the integration of biology into
pediatric clinical trials. ENCCA aims at establishing mechanisms
of prioritization for marker/target/drug selection to be incorpo-
rated into European clinical trials. Speciﬁcally in sarcoma, there
is a high need for early detection of treatment resistant, metasta-
tic, and progressive disease, and for novel therapeutic options for
high risk patients whose survival chances are otherwise still below
30%. Unlike in pediatric leukemia and neuroblastoma, the inter-
national Ewing sarcoma (ES) research community had, so far, not
established a platform for regular meetings and scientiﬁc exchange
that would allow involvement of the whole expert community
into the prioritization process. In the past, the Charles and Dana
Nearburg Foundation kindly sponsored a few valuable ES expert
meetings with limited European participation on the American
side of the Atlantic in irregular, every 3 or 4 years, intervals. Then,
from December 19 to 21, 2011, the ﬁrst ENCCA-supported Euro-
pean Interdisciplinary ES Research Summit was held in Vienna,
Austria. Thirty European and ﬁve North American expert sci-
entists met to exchange and discuss their most recent, largely
unpublished results, and to propose biological studies and novel
promising therapeutics for the upcoming European EWING2008
and EWING2012 studies. Topics ranged from factors affecting the
susceptibility to and pathomechanisms of the disease, tumor stem
cells, and tumor host interactions, over models for the study of
the tissue of origin, mechanisms of metastasis, and drug screen-
ing, to novel diagnostic/prognostic markers and approaches. In
the discussion, particular emphasis was laid on overcoming bot-
tlenecks and the translatability of research results into clinical
practice.
EWS-FLI1 SIGNATURE BASED IDENTIFICATION OF
THERAPEUTIC COMPOUNDS AND DRUG TARGETS
The major driver of ES, the EWS-FLI1 gene fusion, was dis-
covered exactly 20 years ago (Delattre et al., 1992), and there
is ample experimental evidence that inhibition of EWS-FLI1
interferes with tumor growth. EWS-FLI1 is an aberrant tran-
scription factor, and as such it deregulates the expression of a
multitude of genes. Several labs use EWS-FLI1 signature based
approaches to screen for potential therapeutic drugs which mimic
the effects of EWS-FLI1 knockdown, as pioneered by Stegmaier
et al. (2007). Starting from meta analysis of EWS-FLI1 dependent
gene expression data sets, luciferase reporter constructs controlled
by EWS-FLI1 regulated promoters are used for read out in high-
throughput drug screens. The group of Beat Schäfer (University
Children’s Hospital Zurich) monitored EWS-FLI1 activity using
reporters for EWS-FLI1 repressed PHLDA1 and EWS-FLI1 acti-
vated IL1RAP while Lee Helman’s lab (NCI, NIH, Bethesda)
used the NR0B1 promoter for that purpose. Schäfer screened
a LOPAC library (Library of Pharmacologically Active Com-
pounds) of 1280 known compounds and identiﬁed several drugs
already known to be effective against ES including Etoposide
and Doxorubicin but also Idarubicin, 5-Bromo-2-deoxyuridine,
and Fenretinide. Schäfer reported on a particularly active novel
drug, PKC412 (Midostaurin, previously shown to modify phos-
phorylation of PAX-FKHR in alveolar rhabdomyosarcoma), and
presented data on in vitro apoptosis induction and in vivo growth
reduction of ES cell lines in xenografts (Boro et al., 2012)
(Table 1A).
Helman described their preclinical results on mithramycin, an
old antibiotic from streptomyces, which they have identiﬁed in a
56,000 natural product EWS-FLI1 signature based screen (Grohar
et al., 2011) (Table 1A). He reviewed published molecular (inhibi-
tion of EWS-FLI1 cooperating transcription factors SP1, E2F, and
ETS) and ﬁrst clinical results in a patient with ES (Kofman et al.,
1973), and reported on their own ﬁndings of tumor regression in
TC32 xenografts. Consistent with the modulation of EWS-FLI1
signature genes, they found that mithramycin reduces EWS-FLI1
expression.Aphase II clinical trialwith 10patients is about to com-
mence at the NCI andVanderbilt University using mithramycin at
a dose half of what has been previously used, hopefully reducing
the risk of bleeding and other negative side effects. Particularly the
risk of bleeding has been attributed to mitramycin treatment due
to an effect of the drug on platelet function associated with throm-
bocytopenia. As a next step, Helman plans a combination screen
of mithramycin with kinase speciﬁc siRNAs to identify potential
drug sensitizers. But also other, more potent (active at concentra-
tions of 0.3 nM), compounds from the initial screen are currently
under investigation in 22 ES cell lines. Since the ﬁrst EWS-FLI1
signature modulating drug, cytarabine, has failed to induce objec-
tive responses in a phase II clinical trial (DuBois et al., 2009), it
is hoped that these newly identiﬁed compounds will show good
clinical activity and ultimately lead to improved survival rates of
ES patients.
While the mechanisms by which these compounds affect EWS-
FLI1 and/or its downstream signature are still unknown, Jeff
Toretsky (Georgetown University, Washington, DC, USA) pro-
vided an update on their studies of agents directly targeting
EWS-FLI1, the small molecule YK-4-279 and the peptide ESAP1
(Erkizan et al., 2009, 2011) (Table 1A). He reported that differ-
ent enantiomers of YK-4-279 have different biological activity,
offering exciting new opportunities to increase therapeutic efﬁ-
cacy by decreasing IC50 values (i.e., to <1μM for YK-4-279
enantiomer 1).
During the discussion of EWS-FLI1 and signature directed
agents, the question was raised – and left unanswered – as to
which surrogate markers might be used to monitor EWS-FLI1
expression/activity in a clinical setting? This may become a central
issue when following drug response in therapeutic trials.
Frontiers in Oncology | Pediatric Oncology May 2012 | Volume 2 | Article 54 | 2
Kovar et al. Ewing sarcoma research summit
Table 1 | Candidate compounds (A) and biomarkers (B) discussed at the Ewing sarcoma summit.
Compound Target/activity Evidence
A.
Midostaurin (PKC412) Broad spectrum protein kinase inhibitor EWS-FLI1 signature based
Mithramycin Antibiotic EWS-FLI1 signature based
YK-4-279 EWS-FLI1 interacting small molecule Inhibition of EWS-FLI1 protein interaction/activity
ESAP1 EWS-FLI1 interacting peptide Inhibition of EWS-FLI1 protein interaction/activity
Enzastaurin PKC inhibition EWS-FLI1 repressive signature
Tranylcypromine LSD1 inhibition EWS-FLI1 repressive signature
Ubiquitin ligase inhibitors CDT2 inhibition Not discussed
Olaparib, iniparib, veliparib PARP1 inhibition Frequently gained and overexpressed
MLN4294 NEDD8 inhibitor Not discussed
Bisphosphonates (zoledronic acid) Inhibitor of osteoclastogenesis Mouse xenografts
BHQ880 DKK1 inhibitor Osteoblastogenesis induction
IFN-γ Type II interferon Sensitization to TRAIL, inhibition of tumor cell invasion,
and migration
Peptide primed dendritic cells Generation of ES speciﬁc, allo-restricted
T-cells
In vitro and in vivo ES cell lysis
GD2 speciﬁc chimeric antigen receptors (CARs) Generation of antigen speciﬁc T-cells In vitro and in vivo ES cell lysis
IGF1R antibody coupled liposomal doxorubicin Anti IGF1R activity combined with
cytotoxic drug targeting to ES cells
Under development
MST1R (RON), HCK, FES, EPHB2, LMTK2,
PDGFRB
Kinases IGF1R sensitizer RNAi screen
OSI-906 Dual IGF1R/IRA inhibitor In vitro growth inhibition
Metformin Reduces circulating insulin In vitro growth inhibition
CD99 antibody O662 Cell death and autophagy induction In vitro growth inhibition
Nutlin 3 P53 activation In vitro growth inhibition
Biomarker Function Evidence
B.
Telomere length Replicative potential Telomeric repeat PCR
Copy number changes at chromosomes 1q, 8q,
16, and 20
Unknown Array CGH, MLPA
Metadherin (MTDH) Metastasis, chemoresistance Chromosome 8 encoded, frequent gain
CDT2 Protein ubiquitinylation Chromosome 1q encoded, frequent gain
Circulating tumor DNA Marker of tumor load qPCR detection in plasma samples
Circulating miRNAs Marker of tumor load Stem-loop qPCR detection in plasma or whole blood
ErbB4 Metastasis PuMa assay in mouse
STEAP1 Good prognostic marker Retrospective correlative study in patients
LGR5 Stem cell marker Expression study in patient materials
GPR64 G-protein coupled receptor Promotion of lung metastasis
EPHB2 Metastasis associated kinase Comparison of localized and metastatic tumor samples
IRA IGRF1R inhibitor resistance Correlative expression study
EWS-FLI1 MEDIATED GENE REPRESSION AND EPIGENETICS
EWS-FLI1 speciﬁc expression signatures have also been the basis
for integrated genomics approaches to identify key downstream
pathways for potential therapeutic intervention. Heinrich Kovar
(Children’s Cancer Research Institute, Vienna, Austria) reported
on blocked forkhead box (FOX) transcription factor and NOTCH
signaling pathways (Ban et al., 2008; Bennani-Baiti et al., 2011)
in ES, on how NOTCH impacts mechanistically on p53, and
on the in vitro activity of drugs reactivating these pathways.
While these represent examples of indirect EWS/FLI repressed
pathways, Stephen Lessnick (Huntsman Cancer Institute, Salt Lake
City, UT, USA) reported evidence for direct gene repression by
EWS/FLI. Lessnick provided evidence for the involvement of pro-
teins that modulate epigenetic alterations in EWS/FLI mediated
direct repression of critical target genes in Ewing’s sarcoma. Franck
Tirode (Institut Curie, Paris, France) highlighted another EWS-
FLI1 directly regulated epigenetic mechanism of gene repression,
which involves the direct EWS-FLI1 target gene PRKCbeta. This
kinase has been demonstrated to phosphorylate histone H3T6 in
prostate cancer cells controlling demethylation at histone H3K4
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FIGURE 1 | Putative mechanisms of EWS-FLI1 mediated gene regulation
discussed at the Ewing sarcoma summit. EWS-FLI1 serves as a direct and
indirect transcriptional regulator of a multitude of genes. It preferentially binds
to proximal promoter regions directly activating genes, in part in synergy with
other transcription factors such as E2Fs, which are themselves direct
EWS-FLI1 targets. Transcriptional repression downstream of EWS-FLI1 likely
comprises several components. The mechanism of direct repression (which is
frequently associated with distal binding) remains largely unknown. However,
several transcription factors, among them NR0B1, NKX2.2 and, most recently,
repression of FOXO1 have been reported as mediators of indirect
transcriptional repression by EWS-FLI1. There is also accumulating evidence
for the involvement of epigenetic modiﬁers (EZH2, HDACs, PRKCB, LSD1) in
negative transcriptional regulation by the chimeric ETS oncogene. The
consequences of PRKCB mediated histone H3T6 phosphorylation in ES,
previously reported to redirect the demethylating activity of LSD1 from
H3K4Me2 to H3K9Me2 thus favoring gene activation over repression in
androgen dependent prostate cancer (Metzger et al., 2010), remain to be
deﬁned.
(Metzger et al., 2010). Strikingly, Tirode found a strong overlap
between EWS-FLI1 and PRKCB regulated genes in ES and out-
lined a few examples. Thus, epigenetic mechanisms appear to play
a central role in ES pathogenesis (Figure 1).
SUSCEPTIBILITY TO ES AND DISEASE PROGRESSION
Chromatin accessibility regulated by epigenetic mechanisms may
also be responsible for variations in susceptibility to the develop-
ment and progression of the disease. Poul Sorensen (University of
British Columbia Vancouver, BC, Canada) discussed epigenetic
regulation of genes as a source of gene expression differences
between primary ES and matched metastasis derived cell lines.
Under the leadership of Olivier Delattre (Institut Curie, Paris,
France), the question of susceptibility to ES has been addressed
in an international genome-wide association study (GWAS) on
approximately 1500 ES cases and more than 4000 Caucasian con-
trols (Postel-Vinay et al., 2012). Candidate loci have been detected
on chromosomes 1, 10, and 15, and for each of these loci SNPs
in the vicinity of three genes, TARDBP, EGR2, and BMP, have
been discovered independently associating with ES at very high
odds ratios. Also, the SNPs on chromosomes 1 and 10 are very
rare in Africans, consistent with the rarity of ES in this popula-
tion. For EGR2, the risk allele has been found to be associated
with increased, for TARDBP with decreased, expression. TARDBP
on chromosomal region 1p36.22 is of particular interest since its
product, TDP-43, associates with FET (FUS, EWS, TAF15) pro-
teins, and is frequently mutated in amyotrophic lateral sclerosis
(as is FUS, for review Ince et al., 2011).
Although at this point the role of genes in the vicinity of the
enriched SNPs for the development of ES remains unknown, the
ﬁnding of TARDBP as a candidate ES predisposition gene moves
the question of a potential functional interaction of EWS-FLI1
with EWS-containing protein complexes into focus. Pierre Aman
(University of Gothenburg, Sweden) demonstrated coordinate but
heterogeneous expression of all three FET proteins within a tis-
sue as monitored by single cell qPCR and immunohistochemistry.
Similarly, FET fusion product levels show variation. Based on
results on the FUS-DDIT3 gene fusion in myxoid liposarcoma,
Aman hypothesized that there might exist a critical intermedi-
ate FET fusion protein expression level deﬁning a transformation
window, while high expression results in senescence and/or apop-
tosis. Protein interaction studies for EWS and EWS-FLI1 by co-
immunoprecipitation or afﬁnity chromatography are ongoing in
the Aman and Toretsky labs which will help elucidate the func-
tional relationship between FET and associated proteins and their
oncogenic fusions. Preliminary results suggest that one-third of
proteins associated with EWS-FLI1 are spliceosomal while only
about 8% are transcription proteins.
An intriguing new aspect with regard to how gene expression
is regulated in ES and may contribute to disease susceptibility
or progression was provided by Martin Staege (Martin-Luther-
University Halle-Wittenberg, Halle, Germany). He explored the
role of human endogenous retrovirus (HERV) like sequences
which constitute up to 10% of the genome and which are epi-
genetically regulated. Importantly,HERVs do not share homology
with other species. Staege reported on a screen for association
between DNA microarray data and HERV loci (16 Mio putative
HERVs) asking which HERVs are expressed in ES. For that pur-
pose, his group has established a MySQL data base of HERVs and
a PEARL script calculating association between DNA microar-
ray data and HERV loci. He has found a correlation between the
expression of HERVs and ﬂanking genes (as exempliﬁed for MYC
regulated genes). Based on this approach, two types of ES with
different HERV association can be distinguished, but biological
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correlations cannot be drawn yet. In the next step, the group will
address the question, which proteins are encoded by the expressed
HERVs in ES (envelope proteins, superantigens). They have cloned
HERV-env proteins into expression vectors for conditional expres-
sion of these proteins in cell lines. Ultimately, they will investigate
if HERV sequences have an impact on patient survival or immune
response, or may be used as markers for minimal residual dis-
ease detection. So far, validation suffers from the lack of sufﬁcient
clinically annotated materials.
Factors associated with disease progression are of particu-
lar interest as putative prognostic markers. Such biomarkers are
urgently needed for early response prediction particularly in local-
ized disease. Sue Burchill (Leeds Institute of Molecular Medicine,
Leeds, UK) presented preliminary data on telomere length mea-
surements (by PCR of telomeric repeats) in primary ES suggestive
of shorter telomeres being associated with a worse overall (but
not event free) survival (Table 1B). Besides the difﬁculty of deﬁn-
ing a standardized cut-off value for telomere lengths, the lack of
complete clinical data has, so far, not allowed determination of a
possible relationship of this result to patients´ age, which is known
to be of prognostic relevance. Enrique De Alava (Salamanca Uni-
versity Hospital, Salamanca, Spain), Javier Alonso (Instituto de
Salud Carlos III, Madrid, Spain) and Olivier Delattre reported
on array comparative genome hybridization (aCGH) and Multi-
plex Ligation-dependent Probe Ampliﬁcation analyses (MLPA) to
quantify chromosomal and gene copy number variations in ES.
These studies conﬁrm earlier observations by conventional cyto-
genetic and ﬂuorescence in situ hybridization (FISH) methods
(Hattinger et al., 2002; Roberts et al., 2008; Savola et al., 2009) that
themost recurrent copynumber variations of prognostic relevance
are gains of chromosomes 1q, 8q, and 20, and loss of chromosome
16q (Table 1B). Delattre brieﬂy discussed chromosome 8 encoded
MTDH (metadherin, AEG-1), a gene whose overexpression asso-
ciates with metastasis and chemoresistance in several solid tumors
(for review Meng et al., 2011), as a putative drug target in ES. De
Alava reported on two genes on chromosome 1q gained in 31%
of cases, CDT2 and PARP1 (MacKintosh et al., 2011) as potential
therapeutic targets (Table 1B). For many years, PARP1 has been
known to be overexpressed in ES (Prasad et al., 1990). It is involved
in DNA damage repair, and according to De Alava’s presenta-
tion there have been speculations on whether PARP inhibitors
(i.e., Olaparib, Iniparib, Veliparib) may act in synergy with DNA
damage inducing drugs, or whether increased PARP expression
is already a consequence of persistent EWS-FLI1 induced DNA
damage in ES. Early phase clinical trials in ES combining PARP
inhibitors with DNA damaging agents are ongoing (Table 1A).
The discussed genes on chromosomes 1 and 8 are examples for
candidate markers of disease progression. However, it is unlikely
that either a single gene or a single chromosome aberration will
ever enable reliable prediction of prognosis as a basis for therapy
stratiﬁcation. Whole genome targeted methods will be required to
monitor combinations of copy number and sequence alterations.
There was broad agreement that although MLPA and aCGH may
be versatile and comparably easy to establish diagnostic tools in the
context of a clinical trial (as pioneered in the European neuroblas-
toma study), next generation sequencing-based methods would
be optimal for that purpose. Delattre reported that the French
National Cancer Institute (INCa) is willing to fund a pilot exome
and RNA sequencing study of about 100 clinically well annotated
localized and metastatic ES as part of the International Cancer
Genome Consortium, and invited European centers to submit
diagnostic tumor and matched blood/bone marrow (for germline
control) samples. Poul Sorensen reported that the comparison
(whole exome and RNAseq) of matched normal, primary, and
metastasis samples from three metastatic patients revealed that
only 40–70% of SNVs were found to be shared between primary
tumors and metastases. These results are consistent with massive
genetic changes during tumor evolution. Therefore, if one wants
to adopt therapy to progression-associated mutations it is essen-
tial to collect tumor material at a time right before any change
in therapy is initiated, as Lee Helman pointed out. However, Uta
Dirksen (University Hospital, Munster, Germany) mentioned that
in most European pediatric cancer centers – with a few excep-
tions (i.e.,Department of Pediatrics,TechnicalUniversity,Munich,
Germany, as reported by Stefan Burdach) – follow-up tumormate-
rial from metastatic lesions is rarely available, since, mainly for
ethical reasons, protocols simply do not allow for further biop-
sies to be taken after initial diagnosis. In addition, diagnosis is
usually done on ﬁne needle or trephine biopsies critically restrict-
ing the amount of tumor material available for biological studies.
Whole exome sequencing by NGS, however, requires a minimum
of 5μg DNA from fresh tumor tissue, since prior ampliﬁcation
is not recommended. This bottleneck in accessibility of follow-up
tumormaterial calls for non-invasive approaches to follow therapy
response in ES patients.
BIOMARKERS FROM BLOOD AND BONE MARROW
Markus Metzler (University Hospital Erlangen, Germany) pre-
sented results from a pilot monitoring study of circulating tumor
DNA (ctDNA) in the plasma of ES patients during therapy
(Table 1B). After characterization of genomic breakpoints of the
EWS-FLI1 gene fusion on the initial biopsy material by long-range
PCR,ctDNA isolated fromplasma samples during therapy is quan-
tiﬁed by real-time quantitative PCR. This method allows assessing
tumor burden and response to chemotherapy in a minimally inva-
sive way. Preliminary results on 27 patients reveal peaks after each
treatment cycle and Metzler reported on the initiation of a pilot
study in collaboration with the University Hospital Munster.
Tumor speciﬁc microRNA signatures are an area of great diag-
nostic potential. The labs of Heinrich Kovar (Children’s Cancer
Research Institute, Vienna, Austria) and Katia Scotlandi (Rizzoli
Institute, Bologna, Italy) have previously reported on EWS-FLI1
and ES associated miRNA patterns, respectively (Ban et al.,
2010; Nakatani et al., 2011). Kovar’s group found that EWS-FLI1
knockdown decreases AGO2 expression in ES cells, and Günther
Richter (Department of Pediatrics, Technical University, Munich,
Germany) reported that EWS-FLI1 induced EZH2 up-regulates
AGO2, and experimental AGO2 suppression results in decreased
ES tumor growth and metastasis in mice, while AGO1 knockdown
enhances tumorigenicity. Based on speciﬁc ES miRNA signatures,
Sue Burchill suggested the monitoring of circulating microRNAs
(miR) in plasma or whole blood of ES patients as a surrogate
marker for tumor burden (Table 1B). She presented preliminary
data on the use of a 7900miRhigh-throughput stem-loopRT-PCR
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platform for this purpose. The subsequent discussion focused on
the question of tumor speciﬁcity of circulating miR spectra in the
light of chemotherapy induced metabolic and consequently miR
expression changes in many tissues that remain to be deﬁned.
An experimental approach to non-invasive diagnosis of ES
tumor cells was presented by Udo Kontny: the use of CD99 tar-
geted supramagnetic particles, which is currently developed at the
University Hospital Freiburg, Germany.
MODELS FOR EWING SARCOMA RESEARCH
Testing and optimization of appropriate animal models for new
diagnostic and therapeutic approaches require tumor models with
a close histo-pathology match and the right sarcoma microen-
vironment. ES cell lines are amply available to the research
community, but in vitro cultivation, even under non-adherent
conditions as spheroids or in soft agar, does not allow for tumor-
microenvironment interactions. Subcutaneous injection of tumor
cells into immuno compromised mice is most frequently used to
investigate ES growth in vivo. Even though in humans ES never
grow under the skin, this has been a useful research tool for simple
growth studies. Antonio Llombart-Bosch (University of Valencia,
Spain) reported on successful transplantation of 514 primary sar-
coma pieces without dissociation in Nu/Nu BALBc mice, 16 of
which were ES. The avoidance of stress associated with in vitro
manipulation before transplantation resulted in >80% tumor
xenograft take. This model can be used to study early stages of
angiogenesis, and for preclinical therapy testing. Llombart-Bosch
summarized his results on the immunohistochemical character-
ization of xenotransplanted sarcomas with respect to epithelial
markers, CD99, Ki67, caveolin, p16, and p53. A major limitation
of the method is that it does not work with core biopsies, and
tumors have to be transplanted immediately after biopsy.However,
this may in fact more accurately reﬂect ES growth than subcuta-
neously grown tumors following injection of mice with cell line
suspensions.
Richard Moriggl (Ludwig Boltzmann Institute for Cancer
Research, Vienna, Austria) reported that subcutaneous xenograft
tumor growth from ES cell lines activates JAK/STAT signaling
(which has also been observed in 70% of patient derived tumor
materials), presumably via activation through the oncostatin M
receptor, which is also prominently expressed on mesenchymal
stem cells (MSCs). He provided in vitro evidence that treatment
with oncostatin M results in decreased cell adhesion and the
activation of several stemness transcription factors.
As an alternative to subcutaneous injections, Udo Kontny
(University Hospital Freiburg, Germany) reported on the use of
orthotopic xenotransplantation of ES cell lines into the mouse
gastrocnemius muscle in his study of invasive growth into bone
and for perfusion based imaging for early chemotherapy response
detection. Intravenous tumor cell injection followed by in vitro
cultivation of mouse lung slices is a novel potent method to inves-
tigate pulmonary metastasis ex vivo (PuMA assay, Mendoza et al.,
2010). Poul Sorensen adopted this approach for his study of ES and
described the speciﬁc growth conditions and their application to
the investigation of ErbB4 in promotingmigration,metastasis, and
chemoresistance of ES (Table 1B).
Subcutaneous and intravenous injections of ES cell lines have
also been used by Günter Richter (Technical University, Munich,
Germany) to study the role of two EWS-FLI1 induced ES speciﬁc
genes, GPR64 and STEAP1 (Grunewald et al., 2012a) (Table 1B).
Comparing clinical data in patients with in vivo data in the
xenograft models demonstrated the limitations of mouse mod-
els: in patients, high STEAP1 expression is associated with better
survival (Grunewald et al., 2012b) while in the mouse it promotes
tumor cell invasion.
Richard Moriggl gave an update on the development of a
genetic EWS-FLI1 mouse model. Using a similar approach as Lin
et al. (2008), he described the use of a Prx1 Cre recombinase dri-
ven conditional EWS-FLI1 knock-in to target the fusion protein to
mesenchymal progenitor cells. He provided a detailed description
of developmental changes that result in arrest of endochondral
bone formation at an early stage (day 12.5) of chondroblastic
development and the consequences for embryonal limb and cran-
iofacial malformations. He also reported on preliminary results
using a tamoxifen inducible modiﬁcation of this model to turn-on
EWS-FLI1 in the mesenchymal lineage after birth. So far, however,
there is no indicationof successful sarcomagenesis induction in the
mice and further genetic modiﬁcations are necessary to develop a
robust model.
Zebraﬁshmodels are increasingly used as an alternative tomice.
There is a plethora of genetic variants available, they are easy to
manipulate and breed, and, because of their transparency, sim-
ple to monitor. Pancras Hogendoorn (Leiden University Medical
Center, Leiden, Netherlands) pointed out that bone development
and the involved cytokines in zebraﬁsh are highly homologous
to mammals and they could, therefore, be particularly useful for
studying bone sarcomas. He gave examples of research projects
studying invasion, angiogenesis, andmetastasis after yolk sac injec-
tionof ES cells. Thebeauty of thismodel is that invasion,angiogen-
esis, and tumor cell spread can be followed in real-time under the
confocalmicroscope. Tumorhost interactions canbe easily studied
by discrimination of human and ﬁsh genes. Preclinical lead devel-
opment can proﬁt from high-throughput screening of thousands
of ﬁsh in a simple 96 well format in a single 1 week experiment
under standardized experimental conditions. Poul Sorensen, with
his collaborator Jason Berman of Dalhousie University in Halifax,
used the zebraﬁsh model to study the interaction of the splicing
factor YB1 with EWS-FLI1. They found that hypoxia is inducing
YB1, which increases polysomal (translated) HIF1α mRNA while
decreasing translation of proliferation genes like CCND1 (Evdoki-
mova et al., 2009), potentially affecting angiogenesis. Hogendoorn
mentioned that zebraﬁsh can be bred at temperatures as high as
34˚ to approach the human situation, and it was discussed whether
these conditions could result in a kind of permanent heat shock. In
addition, Hogendoorn reported on an in vitro 3D matrix model,
in which tumor cells are inoculated into agar in 96 well format
by robotic spotting with subsequent automated monitoring of
outgrowth by a digital camera.
TUMOR INITIATING CELLS
The efﬁciency of engraftment of solid tumor cells in mice and ﬁsh
depends on the content of tumor initiating cells which are known
to be particularly chemo resistant. Previously, such properties have
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been assigned to a small subpopulation of CD133 positive ES cells
(Suva et al., 2009), which has subsequently been challenged by
other researchers (Jiang et al., 2010). Uta Dirksen described the
properties of a side population of ES cells as candidate tumor ini-
tiating cells. She found that this population of small cells retained
pluripotency in differentiation assays, and led to increased soft
agar colony growth associated with high tumor induction in
mouse xenografts at subcutaneous and intravenous injection of
only a few thousand cells of this particular side population of ES
cells. The, presumably, tumor initiating sarcoma cells displayed
increased chemoresistance to Doxorubicin and Etoposide. Impor-
tantly, these cells did neither express consistent stem cell marker
(i.e., CD133 negative), nor increased levels of ABC transporters,
and no stem cell transcription factors NANOG, OCT4, or SOX2.
Elizabeth Lawlor (University of Michigan) talked about expres-
sion and putative role in ES stem cells of the transmembrane
protein LGR5 (GPR49). LGR5 is a well established stem cell
marker highly expressedduring embryonic development andpost-
natally in normal hair follicle and intestinal stem cells. High-levels
of LGR5 are also associated with tumor initiation, cancer stem
cells, and early relapse in colorectal cancer (Merlos-Suarez et al.,
2011; Walker et al., 2011). LGR5 is a canonical Wnt target gene
and recent data show that activation of LGR5 by its ligands, the
R-spondin family of matricellular proteins, also potentiates canon-
ical β catenin/Wnt signaling and activates stem cell proliferation
(de Lau et al., 2011). R-spondins are expressed in developing bone
and Lawlor has found that human neural crest stem cells and
subpopulations of ES cells express LGR5. Ongoing studies are
determining if LGR5 is just a marker or whether it is function-
ally involved in tumor initiation, stemness, and chemoresistance
of ES cells (Table 1B).
TARGETING TUMOR/MICROENVIRONMENT INTERACTIONS
AND THE IMMUNE SYSTEM
Besides the need for deﬁning the subpopulation of chemoresistant
tumor (stem) cells responsible for disease recurrence, tumor-
microenvironmental interactions may offer entry points for sup-
portive therapies. Françoise Redini (INSERM U957, Nantes,
France) investigated the activity of bisphosphonates (i.e., Zole-
dronic acid) to inhibit osteoclastogenesis (Table 1A). Osteolysis
is an important mechanism of many bone targeting neoplasms
to generate space for tumor growth. In turn, osteoclasts release
factors promoting tumor cell growth. ES express RANKL which
is known to stimulate osteoclastogenesis. In addition, primary
ES contain high-levels of M-CSF and TNF-α, which might be
secreted from tumor inﬁltrating macrophages. Since osteoclasts
are hardly detectable in ES, macrophages may take their role in
osteolysis and tumor stimulation. Redini reported that Zoledronic
acid (Zometa, Novartis) induced caspase 3 dependent apoptosis
of tumor cells in vitro and bone tumor regression in mice (Odri
et al., 2010). In addition she demonstrated that ectopic soluble
RANKL receptor osteoprotegerin (OPG), soluble TNF receptor,
and DKK1 inhibitors (BHQ880, Novartis) inhibit ES growth by
stimulating osteoblastogenesis (as monitored by increased bone
marker expression) (Table 1A).
Inﬂuencing the interaction between the tumor and the immune
system is a further area of hope in novel ES therapy approaches.
About 50% of ES are resistant to the apoptotic function of TRAIL.
Udo Kontny and others had previously demonstrated that despite
expression of TRAIL receptors DR4 and DR5, about 25% of
tumors have low expression of caspase 8 and do therefore not
respond to TRAIL treatment. IFN-γ had been shown to sensi-
tize TRAIL-mediated apoptosis by upregulation of Caspase 8 in
neuroblastoma and ES (Yang et al., 2003; Lissat et al., 2007) and to
inhibit the formation of metastases in mice (Merchant et al., 2004)
(Table 1B). Kontny now reported that they found IFNgamma to
inhibit invasion andmigration of ES cells in vitro. Redini described
a novel TRAIL receptor isoform on ES cells, a truncated DR4.
It remains to be established, how this isoform may be involved
in TRAIL resistance of tumor cells (Picarda et al., 2012). Gün-
ter Richter provided evidence that the EWS-FLI1 induced protein
GPR64, which regulates expression of the metalloprotease MMP1,
critically promotes lung metastasis. Moreover, experimental sup-
pression of GPR64 expression rendered tumor cells more sensi-
tive to TRAIL and chemotherapy causing decreased local tumor
growth (Table 1B).
Richter also described the experimental approach that Stefan
Burdach´s group at the Technical University of Munich is taking
to generate ES speciﬁc T-cell responses by in vitro priming (pep-
tide non-amers) of dendritic cells. After selection of T-cells with
peptide-MHC-pentamer-ﬂuorophores, ES speciﬁc allo-restricted
T-cells were shown to speciﬁcally kill tumor cells in vitro and upon
tail vein injection in immunocompromised mice they delayed ES
growth (Thiel et al., 2011). Based on this approach, a clinical trial
is planned to be initiated in 2013 (Table 1A).
Claudia Rössig (University Children’s Hospital Münster, Ger-
many) explored the use of chimeric antigen receptors (CARs),
that is T-cell receptor signaling domains linked to a tumor anti-
gen speciﬁc antibody chain, to generate antigen speciﬁc T-cells
for ES immunotherapy (Park et al., 2011; Kalos, 2012). She sug-
gested using CARs for the carbohydrate GD2 that have recently
been successfully applied successfully to the treatment of neurob-
lastoma (Louis et al., 2011) (Table 1A). She found surface GD2
in 11/11 ES cell lines and 3/3 primary cell cultures (Kailayan-
giri et al., 2012). Moreover, diagnostic ES biopsies from 12 of 14
patients had uniform GD2 expression. Anti-GD2 CARs lyse ES
cells under adherent growth conditions and in spheres (six cell
lines) and have anti-tumor activity in an ES xenograft model.
These CARs also work in an autologous setting. The theoretical
potential of autoimmune reactions against other GD2 expressing
cell types, such as mesenchymal and neural crest derived stem
cells, limiting the clinical application of this approach, remains
to be established. To test if a patient may be eligible for a GD2-
directed immunotherapy, GD2 expression has to be assessed on
frozen sections.
Rössig further discussed the pros and cons of using natural
killer (NK) cells as alternative innate immune effector cells to anti-
gen speciﬁc T-cells.WhileNK cells aremore potent in direct tumor
cytolysis than T-cells, they do not persist in vivo for extended peri-
ods. She suggested to expand NK cells from ES patients and com-
bine the signaling lymphocyte activation molecule-related recep-
tor 2B4 (CD244) with an anti-GD2 antibody chain to produce
CARs that overcome NK cell resistance of ES, as she had previously
demonstrated in neuroblastoma (Altvater et al., 2009) (Table 1A).
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THE IGF PATHWAY AND BEYOND
A well known pathway of tumor host interaction in ES patients is
IGF1R signaling. Initial enthusiasm for IGF1R directed antibodies
and smallmolecules to treat ES patients with refractory or relapsed
disease has decreased, reﬂecting limited effectiveness in vivo (Ho
and Schwartz, 2011). To improve efﬁcacy, Udo Kontny reported
on the development of an experimental therapy using IGF1R anti-
body coupled to liposomal doxorubicin (Table 1A). Jenny Potratz
(University Children’s Hospital Muenster, Germany) reported on
the results of an RNAi screen for sensitizers to IGF1R inhibitors
and described a number of promising kinases includingHCK,FES,
EPHB2, LMTK2, PDGFRB). By comparing 15 localized tumors to
six metastases and four MSC samples, they ﬁltered out EPHB2
which was differentially expressed and thus deﬁnes a candidate
target for treatment of aggressive disease. The top candidate kinase
sensitizing to IGF1R inhibitors was found to be MST1R (RON), a
cMET related receptor tyrosine kinase (RTK; Potratz et al., 2010)
(Table 1A).
Katia Scotlandi identiﬁed a mechanism of resistance to IGF1R
targeting compounds. She found that ES cells upregulate Insulin
Receptor A (IRA) which binds to IGF2 (Garofalo et al., 2011).
She therefore suggested to co-target IGF1R and IRA. The EU-
FP7 funded project EUROSARC will initiate a phase I trial for
co-targeting using the dual inhibitor OSI-906 (Table 1A). Alterna-
tively, the antidiabetic drug Metformin, which decreases circulat-
ing insulin,mayhold promise for the treatment of ES (Table 1A). It
has been demonstrated to display anticancer activity by depriving
cells of insulin, inhibiting mTOR, and decreasing AMPK involved
in anoikis resistance (Del Barco et al., 2011; Ng et al., 2012). So far,
all tested ES cell lines, even IGF1R resistant ones, have proved to be
sensitive to metformin, though very high concentrations of met-
formin (10mM) were required. Under these conditions, Scotlandi
also observed Metformin to reactivate p53.
Scotlandi also discussed several other p53 reactivating drugs
(i.e., Nutlin 3) and addressed the role of CD99 targeting anti-
body 0662 for the induction of caspase independent cell death and
autophagy in ES (Table 1A). Simone Fulda (Goethe-University,
Frankfurt, Germany) discussed the role and therapeutic poten-
tial of the Hedgehog pathway comparing fusion negative alveolar
rhabdomyosarcoma to ES. Other drugs and pathways of rele-
vance to ES that were addressed during the meeting but not
mentioned above comprise the PKC inhibitor Enzastaurin (F.
Tirode), the NEDD8 inhibitor MLN4294, and protein ubiquitin
ligase inhibitors (E. De Alava) (Table 1A).
CONCLUSION AND NEXT STEPS
In order to move the huge amount of new biological knowl-
edge presented at the meeting forward to the clinics, feasibil-
ity, and quality criteria were discussed. Experience from the
EuroE.W.I.N.G.99 study (Le Deley et al., 2010; Le Deley et al.,
unpublished) has taught us to keep prospective marker studies
in the context of multicentric clinical trials as simple as possible.
EnriqueDeAlava suggested toﬁrst performameta analysis of exist-
ing retrospective data for a candidate marker before proceeding to
prospective evaluation – even though the validity of retrospective
studies may be doubted due to the frequent incompleteness of
clinical data. Such retrospective tumor collections exist in Valen-
cia, where Antonio Llombart-Bosch has built an impressive tumor
bank with samples from 841 ES cases, and 24 tissue arrays with
604 cases. This ES biobank has been entered into the virtual tumor
bank of the European network of excellence EuroBoNet. Lim-
ited clinical data exist for about 270 cases which have been used
recently to establish high desmoplakin expression as a good prog-
nostic indicator. As a reference lab for the Spanish SEHOP study,
141 ES (120 frozen samples and tissue arrays) have been collected
by Javier Alonso in Madrid. Clinically well annotated retrospec-
tive ES tumor banks, partly with genomic data (gene expression),
already exist in Münster, Leeds, and Paris with samples from the
European ES studies EICESS92 and EuroE.W.I.N.G.99. In addi-
tion, the German TranSaRNet supports a tumor bank on relapsed
sarcoma, SAREZ.
Limitations in the availability of unﬁxed biopsy materials are
commonly recognized as the most severe bottleneck for marker
studies. Poul Sorensen pointed to tumor heterogeneity as a prob-
lem that does not allow detection of rare tumor driving cells when
grinding the whole tumor. Assay development on ﬁxed material is
therefore urgently needed, and pathologists should routinely pro-
duce tissue micro arrays (TMAs) from the biopsies of all patients
entered prospectively into a clinical trial.
Yet, since the causes of metastasis are still unknown, it remains
doubtful whether the analysis of diagnostic samples from the pri-
mary tumor of patients with localized disease before therapy will
allow prediction of chemotherapy response and relapse. There-
fore,we should focus on collecting tumormaterial frommetastatic
patients and during disease progression. In order to guarantee
the same quality of samples and avoid bias in an international
multi centric setting, emphasis should be placed on (i) the num-
ber of samples, (ii) the stability of targets, (iii) the availability of
standard operating procedures (SOPs) for sample collection, pro-
cessing, and diagnostic assays, (iv) a low inter- and intra assay
variability, (v) a high degree of practicability, (vi) built-in qual-
ity controls, (vii) guaranteed availability and quality of clinical
data, and lastly (viii) funding. EuroBoNet has already established
SOPs for sample preparation and processing; these are available
through the EuroBoNet website. Apart from putative prognos-
tic markers discussed at the meeting, participants considered the
prospective evaluation of already established copy number vari-
ations by aCGH or MLPA, complemented by exploratory exome
sequencing, to be the highest priority. In addition, the investigation
of ctDNA in blood and bonemarrowwas viewed as an area of great
promise for non-invasive assessment of therapy response. Con-
sidering novel therapies, participants pleaded for the introduction
of more experimental therapies into the treatment of metastatic
patients. After 2 days of discussions at this meeting, participants
consideredPARP inhibitors andmitramycin as themost promising
agents for this purpose. In addition, a need for more pharmacoge-
netic andpharmacogenomic studieswas expressed to assess factors
of resistance/sensitivity to conventional chemotherapies.
Through the Biology and Sarcoma Workpackages (chaired by
Angelika Eggert, University Clinics, Essen, Germany, and Stefan
Bielak, Olga Hospital, Stuttgart, Germany) these suggestions will
be presented to the European Ewing sarcoma study groups for
consideration in the design of Ewing2008 and Ewing2012 trials.
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